Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

0 YEARS OLD: RESULTS

OF A PHASE 1 STUDY

Abstract #0515

Poster session 2: Acute myeloid leukemia -- Clinical II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

o A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9

INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Abstract #0792

Poster session 2: Novel therapies, drug resistance and pharmacology II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

All clinical data presented will be available following each conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling.

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leuke
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... YORK , Aug. 29, 2014 Pomerantz ... TMS S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ... filed in United States District Court, Southern District of ... 14-cv-6069, is on behalf of a class consisting of ... February 1, 2013 and July 30, 2014, inclusive (the ...
(Date:8/29/2014)... PARK, Calif. , Aug. 29, 2014 ... Medical as CEO and member of the Board of ... decades of medical device development and commercialization experience, including ... field. Mr. Engelson previously served as a Partner of ... as President and CEO of two Foundry start-ups. Mr. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2
... Digital Assent, provider of the award-winning PatientPad® self-service ... that it has appointed Frank Garland as vice president ... Garland will focus on increasing the digital advertising and ... the company,s New York sales office. "Frank ...
... Oct. 20, 2011 Bend Research Inc. ( www.bendresearch.com ... has announced that John McLeod has joined the company ... http://photos.prnewswire.com/prnh/20111020/CL87178 ) McLeod was formerly Director ... six years, where his strategic vision is credited with ...
Cached Medicine Technology:Digital Assent Names Frank Garland Vice President of Advertising Sales 2Bend Research Announces New Chief Financial Officer 2
(Date:9/1/2014)... is a leading review website in the world. It ... announced that GreenGeeks, Arvixe and Hostgator are the best ... http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ) is one of the best web hosting ... of useful products for sale. On its website, customers ... , As one of the Top 10 Web Hosting ...
(Date:9/1/2014)... Television shows filled with action and sound may be ... cookies, carrots and grapes while watching an excerpt from ... program. , , Television has been blamed for helping ... lifestyle. But the focus of why has been on ... other distracting activities that can cause people to eat ...
(Date:9/1/2014)... News) -- You may be able to convince your brain ... suggests. The study included eight overweight and obese people ... to change how people react to different foods. These participants ... obese people who weren,t in the program. Both groups ... and again six months later. The scans revealed that the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 An operating ... a hospital for performing surgical operations. An operating room ... tables, surgical booms, operating room lights, imaging displays as ... a report by Transparency Market Research, a U.S.-based market ... to reach USD 4.5 billion by 2019. , ...
(Date:9/1/2014)... Dennis Thompson HealthDay ... An experimental Ebola drug previously given to two American aid ... deadly virus in laboratory tests, researchers report. The drug, ... even if they didn,t get the medication until five days ... of Ebola who were days or even hours away from ...
Breaking Medicine News(10 mins):Health News:The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com 2Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Train Your Brain to Choose Fruit Salad Over French Fries 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3
... to develop the colorectal polyps that can precede colon cancer. ... patients attending for colonoscopy. They found the incidence of polyps// ... cancer - to be greater among current smokers than in ... likely to have more than two polyps, growths greater than ...
... of the antioxidant vitamin E may assist in reducing ... Health Study and the Health Professionals Follow-Up Study', presented by ... Parkinson's disease. The participants have been followed up for several ... ,Those with a high intake of vitamin E ...
... UK inserting a coil into a weakened blood vessel offers ... rate from subarachnoid haemorrhage// - caused by a bursting of ... to 40 per cent in the first 24 hours after ... a clip to prevent further rupture of the blood vessel. ...
... medical centers hope to arbitrate whether a laser can stop ... two forms of macular degeneration, wet and dry. //The dry ... by the formation of yellowish deposits within the layers of ... have a gradual loss of vision. While there are a ...
... researchers of University of Kansas it is observed that poorly ... pain, gas and diarrhea.// Often people suffer from bowel symptoms ... can be found. They have found out that a high ... to digest fructose. ,Found in honey, fruits and ...
... that endometriosis is linked to infertility. There has long ... shows one of the reasons why the disease may ... patients, but concluded that endometriosis causes a certain action ... fluid located near the fallopian tubes. They then studied ...
Cached Medicine News:
This is the second generation of the famous A/O sliding microtome, manufactured in the United States under the Leica trademark....
... base sliding microtome offers the ultimate in ... not least, safety. ,Designed to meet the ... 8000 will also meet the more demanding ... versatility and wide range of accessories will ...
... MNL 440601 Small Sledge Microtome is ideal for ... or skin specimens. Specimen rise is automatic ... 30 microns in increments of 2 microns. ... Stages.,Other Associated Products, Vibratomes Freezing Stages ...
... is a solid solution for setting ... the Vibratome Plus, standard accessory kit, ... mounts w/1/2" head, and a rotating ... of your sectioning needs.,For selection assistance, ...
Medicine Products: